Get to know our clinical trials
Clinical trial of intravitreal JNJ-81201887 and sham procedure for the treatment of GA secondary to age-related macular degeneration.
THE OBJECTIVE OF THIS STUDY IS TO SEE IF JNJ-81201887 (ALSO CALLED AAVCAGSCD59) IS SAFE AND USEFUL FOR TREATING PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION.
- PHASE IIB, RANDOMIZED, DOUBLE-MASKED, MULTICENTER, DOSE-FINDING, DOSE-CONTROLLED, SHAM-CONTROLLED CLINICAL STUDY TO EVALUATE INTRAVITREAL JNJ-81201887 (AAVCAGSCD59) VS. SHAM FOR THE TREATMENT OF GEOGRAPHIC ATROPHY (GA) SECONDARY TO AGE-RELATED MACULAR DEGENERATION (AMD)
- Code EudraCT: 2022-500746-16-00
- Protocol number: 81201887MDG2001
- Promoter: Janssen-Cilag
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.